ناشر تخصصی کنفرانس های ایران

لطفا کمی صبر نمایید

Publisher of Iranian Journals and Conference Proceedings

Please waite ..
Publisher of Iranian Journals and Conference Proceedings
Login |Register |Help |عضویت کتابخانه ها
Paper
Title

Circulating Tumor BRAF Mutation and Personalized Thyroid Cancer Treatment

Year: 1395
COI: IPMCMED01_059
Language: EnglishView: 319
نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

Authors

Fatemeh Khatami - Chronic Disease Research Center, Endocrinology and Metabolism Population Science Institute, Tehran University of Medical Sciences, Tehran, IRAN
Ramin Heshmat - Chronic Disease Research Center, Endocrinology and Metabolism Population Science Institute, Tehran University of Medical Sciences, Tehran, IRAN
Seyed Mohammad Tavangar - Department of Pathology, Doctor Shariati Hospital, Tehran University of Medical Sciences, Iran
Bagher Larijani - Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences , Iran

Abstract:

Common medical treatments have some difficulties for cancer therapy in a desire way because of resistance to current therapeutics. Personalized cancer therapy aims to understand the unique properties and dynamics of each patient’s cancer in order to provide the most rational and appropriate therapy. It is still under the debate that circulating tumor markers will take the place of standard tissue biopsy or will support it to guide us to the more effective interventions According to American Cancer Society 62,450 people diagnosed with thyroid cancer in 2015 and 1950 deaths will result from the disease. In spite of good prognosis of differentiated thyroid carcinoma (DTC), about five to ten percent of patients will develop metastasis and fail torespond to radioactive iodine (RAI), and other traditional therapies. The lack of effectivetherapies for DTC, resistant to radioiodine and traditional therapies is now being overcome by the development of targeted novel compounds.The published result related to a phase II clinical study in Philadelphia illustrated treating metastatic thyroid cancer patients with the targeted therapy Vemurafenib to establish the activity of Vemurafenib in patients with BRAFV600E-positive papillary thyroid. The large-scale drug screening that incorporates genomic and gene expression data is another breakthrough to identify drug response biomarkers that could inform optimal application of cancer drugs. It is a commonknowledge that a small piece of a tumor receiving after tissue biopsy doesn’t represent the whole tumor, let alone metastases. Liquid biopsy, which is a diagnostic concept, opens a newperspective for real time monitoring of cancer open a new perspective for tumor evaluation.Liquid biopsy is defined as circulating tumor cells (CTCs) and fragments of circulating tumorDNA (ctDNA) shed into the bloodstream from primary and metastatic tumor deposits. Using ofctDNA is superior as a non-invasive and cost effective solution to identify reliable biomarkers for measuring tumor growth, metastasis and response to treatments. Liquid biopsies could be used to guide cancer treatment strategy and perhaps even screen for tumors that are not yet visible on imaging. Take advances in molecular genetic technology into consideration, evaluation and characterization of circulating tumor markers can be the best alternative for realtime tumor tracking. In the near future tissue biopsy will be replaced by liquid biopsy and now is the exact time to focus on CTCs and ctDNA as a circulating tumor biomarker specifically in personalization of cancer treatment.

Keywords:

BRAF mutation, Thyroid Cancer, Personalized Medicine

Paper COI Code

This Paper COI Code is IPMCMED01_059. Also You can use the following address to link to this article. This link is permanent and is used as an article registration confirmation in the Civilica reference:

https://civilica.com/doc/807062/

How to Cite to This Paper:

If you want to refer to this Paper in your research work, you can simply use the following phrase in the resources section:
Khatami, Fatemeh and Heshmat, Ramin and Tavangar, Seyed Mohammad and Larijani, Bagher,1395,Circulating Tumor BRAF Mutation and Personalized Thyroid Cancer Treatment,First Personal Medical Congress,Tehran,https://civilica.com/doc/807062

Research Info Management

Certificate | Report | من نویسنده این مقاله هستم
این Paper در بخشهای موضوعی زیر دسته بندی شده است:

اطلاعات استنادی این Paper را به نرم افزارهای مدیریت اطلاعات علمی و استنادی ارسال نمایید و در تحقیقات خود از آن استفاده نمایید.

Scientometrics

The specifications of the publisher center of this Paper are as follows:
Type of center: علوم پزشکی
Paper count: 7,945
In the scientometrics section of CIVILICA, you can see the scientific ranking of the Iranian academic and research centers based on the statistics of indexed articles.

New Papers

Share this page

More information about COI

COI stands for "CIVILICA Object Identifier". COI is the unique code assigned to articles of Iranian conferences and journals when indexing on the CIVILICA citation database.

The COI is the national code of documents indexed in CIVILICA and is a unique and permanent code. it can always be cited and tracked and assumed as registration confirmation ID.

Support